W

ASHINGTON — Three years after Martin Shkreli became the poster boy of pharmaceutical company greed, another drug company executive is setting himself up for a similar infamy. And now, just as then, there is little the government can do — besides make a fuss.

Nirmal Mulye, CEO of Nostrum Laboratories, quadrupled the price of a generic liquid antibiotic used to treat bladder infections, the Financial Times reported Tuesday. And he had little shame.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Maximizing return, ie by jacking up prices as high as possible, is actually a legal obligation of the CEO towards shareholder under US law, unless the company is organized as B-Corp. The only limit would be if the action of the CEO would short or long-term damage share holder value. The correct response would be to change US corporate law and not to moralize about its ethics and consequences, while the CEO is exposed to share holder lawsuits. Two sides of the coin!

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy